Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul;19(7):1074-83.
doi: 10.3201/eid1907.121830.

Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.)

Sandra S Richter  1 , Kristopher P Heilmann, Cassie L Dohrn, Fathollah Riahi, Daniel J Diekema, Gary V Doern
Affiliations

Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.)

Sandra S Richter et al. Emerg Infect Dis. 2013 Jul.

Abstract

Serotyping data for pneumococci causing invasive and noninvasive disease in 2008-2009 and 2010-2011 from >43 US centers were compared with data from preconjugate vaccine (1999-2000) and postconjugate vaccine (2004-2005) periods. Prevalence of 7-valent pneumococcal conjugate vaccine serotypes decreased from 64% of invasive and 50% of noninvasive isolates in 1999-2000 to 3.8% and 4.2%, respectively, in 2010-2011. Increases in serotype 19A stopped after introduction of 13-valent pneumococcal vaccine (PCV13) in 2010. Prevalences of other predominant serotypes included in or related to PCV13 (3, 6C, 7F) also remained similar for 2008-2009 and 2010-2011. The only major serotype that increased from 2008-2009 to 2010-2011 was nonvaccine serotype 35B. These data show that introduction of the 7-valent vaccine has dramatically decreased prevalence of its serotypes and that addition of serotypes in PCV13 could provide coverage of 39% of isolates that continue to cause disease.

Keywords: Streptococcus pneumoniae; United States; bacteria; conjugate vaccines; pathogenesis; serotype; streptococci; vaccine.

PubMed Disclaimer

Figures

Figure
Figure
Serotype distribution of penicillin-nonsusceptible Streptococcus pneumoniae (PNSP) (MIC >0.12 μg/mL) United States, 1999–2011. Values above bars are percentages.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization: WHO position paper. Wkly Epidemiol Rec. 2007;82:93–104 . - PubMed
    1. Centers for Disease Control and Prevention. Active bacterial core surveillance report. Emerging infections program network, Streptococcus pneumoniae, 2010. [cited 2103 Feb 24]. http://www.cdc.gov/abcs/reports-findings/survreports/spneu00.html
    1. Atkinson W, Wolfe S, Hamborsky J, editors. Epidemiology and prevention of vaccine-preventable diseases. 12th ed. Washington (DC): Public Health Foundation; 2012.
    1. Doern GV, Heilmann KP, Huynh HK, Rhomberg PR, Coffman SL, Brueggemann AB. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999–2000, including a comparison of resistance rates since 1994–95. Antimicrob Agents Chemother. 2001;45:1721–9 . 10.1128/AAC.45.6.1721-1729.2001 - DOI - PMC - PubMed
    1. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med. 2000;343:1917–24 . 10.1056/NEJM200012283432603 - DOI - PubMed

Publication types

MeSH terms